Avicanna recently announced the supply and licensing agreement for two products.
In a recent press release (1), Avicanna, “a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products”, recently disclosed the supply and licensing agreement for two topical products with a multinational pharmaceutical company (Pharma).
“We look forward to expanding our proprietary topical products into the European region and to be doing so through the utilization of our own international infrastructure for manufacturing,” Aras Azadian, CEO of Avicanna, said. “We are confident that through this strategic relationship and the Pharma’s established commercial infrastructure, we can facilitate the expansion of our proprietary products into several international markets.”
The multinational pharmaceutical enterprise markets and produces a variety of pharmaceutical products throughout four continents (1). Pharma has also built a commercial infrastructure in Europe where the products involved in the supply and licensing agreement will be introduced. In 2024, the company intends to market the items in six European countries, which will be expanded in the future. Licensing fees will be awarded to Avicanna and both companies have reached an agreement on minimum order quantities and Pharma’s efforts on exclusivity (1).
According to the press release, the products involved with the agreement are (1):
The Ultra-CBD cream is a 3% cannabidiol (CBD) localized cream developed to target dermatology conditions. The cream is enrolled in previously announced observational real world evidence clinical trial with the Hospital for Sick Children related to Epidermolysis Bullosa.
The Ultra-CBD cream and CBG Transdermal Gel both have completed dossiers and are planning to be commercialized and registered through cosmetics legislation applicable to the products (1). With those needs met, the product offerings are anticipated to be introduced to the marketplace sometime within the first half of 2024.
Reference
Collaboration, Gender Diversity, and Progress: Julie Kowalski on Advancing Cannabis Science
December 10th 2024In this interview with Cannabis Science and Technology, Julie Kowalski, an experienced analytical chemist, discusses her path into the cannabis industry, starting with early work in gas chromatography. Kowalski reflects on her perspectives as a female scientist, highlighting biases she’s experienced and the benefits of gender inclusivity in the cannabis space. Greater unity and professionalism could benefit the industry as a whole, she explains. She also encourages collaboration and more women in leadership positions in order to build a stronger scientific community, and also urges women to advocate for themselves, noting that women in cannabis face unique obstacles but often demonstrate consensus-building strategies and solutions.
Ep 24, Part I: Data Transparency in Cannabis Testing with Yasha Khan
November 21st 2024Evan Friedmann interviews Yasha Khan, co-founder of MCR Labs, about his journey into the cannabis industry and his efforts to promote transparency and integrity in laboratory practices. Yasha discusses the origins of MCR Labs, which began in Massachusetts to meet the needs of the soon-to-be legal medical cannabis market. He explains the challenges faced, including result manipulation by labs and the impact on public health. Yasha's Freedom of Information Act (FOIA) project aimed to gather testing data from 37 states, revealed significant discrepancies in potency and mold results. Despite some states' reluctance to share data, Yasha has made much of this data public, leading to collaborative research and publications on various aspects of cannabis testing.
Gender Diversity and Innovation in the Cannabis Space: Insights from Tess Eidem, PhD
December 9th 2024Cannabis Science and Technology sat down with Tess Eidem, PhD, PCQI, member of Saturn Scientific, LLC, to discuss her journey from antibiotic research to cannabis microbiology and her observations throughout her career. Dr. Eidem highlights challenges women face in this male-dominated industry, including limited representation in leadership roles and frequent experiences of bias and discrimination. She emphasizes the importance of gender diversity in fostering innovation, improving product safety, and addressing women’s health needs in cannabis applications. Her advice to women scientists is to build strong professional relationships and carefully evaluate work environments to advance their careers in this evolving and often challenging space.
Ep 23, Part III: Accreditation in the Cannabis Industry with Susan Audino
October 24th 2024In Part III of this episode, host Evan Friedmann is joined by Susan Audino, PhD, founder of S.A. Audino & Associates, LLC, and co-founder of Saturn Scientific, LLC, to examine the complexities of sampling in the cannabis industry, emphasizing the need for proper sampling plans, and methods.